Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24817956 | 0.85 | KCNH2 (0.34) | PTPN2EIF4A3 | |
| SCHEMBL25465420 | 0.83 | PTPN2 (0.39) | PTPN2ALDH1A1GAATHRBL3MBTL1 | |
| SCHEMBL25465577 | 0.78 | ALDH1A1 (0.38) | PTPN2ALDH1A1GAATHRBL3MBTL1 | |
| SCHEMBL27358363 | 0.78 | POLB (0.38) | PTPN2GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL25828856 | 0.76 | EIF4A3 (0.38) | EIF4A3 | |
| SCHEMBL24316260 | 0.74 | KCNH2 (0.48) | HRH3 | |
| SCHEMBL15785388 | 0.73 | EIF4A3 (0.34) | ALDH1A1EIF4A3 | |
| SCHEMBL26575966 | 0.73 | HRH3 (0.42) | PTPN2HRH3 | |
| SCHEMBL26141147 | 0.73 | EIF4A3 (0.36) | EIF4A3 | |
| SCHEMBL2741634 | 0.72 | OGA (0.43) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | PTPN2 787/4885ALDH1A1 2487/4885GAA 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.